Copyright ©​ Daniel Cullinane CPA.

​AMERICAN FOREIGN POLICY

​REAL ESTATE 

President Trump's move to exit the Paris climate deal will alienate US allies and trade partners that had counted on the US to play a big part in the deal. Domestic energy use and enviromental rules will not change dramatically just because Washington has left the global pact on limiting carbon dioxide emissions. Many states and cities will maintain their own climate policies, regardless of Trump's decision, local limits on fossil fuel use, subsidies for renewable power US carbon emissions will keep falling driven by the continuing shift that began a decade ago from coal to cheap plentiful gas for power generation.  

Nike Inc. (NYSE: NKE) closed out last week with a bang, after the apparel giant reported its fiscal fourth-quarter earnings. Management believes that Nike is poised for a big year, but there seem to be mixed feelings in the analyst community. Some analysts are coming to defend the Swoosh while others think apparel trends might be hurting Nike.

24/7 Wall St. has included some brief highlights from the earnings report, as well as what analysts are saying after the fact.

The company posted $0.60 in earnings per share (EPS) and $8.68 billion in revenue. That compares to consensus estimates from Thomson Reuters that called for $0.50 in EPS and revenue of $8.63 billion. In the same period of last year, Nike posted EPS of $0.49 and $8.24 billion in revenue.

In terms of the revenue breakdown, the Nike Brand revenue was up 7% at $8.1 billion and the Converse Brand revenues were up 10% at $554 million. The business segments within the Nike brand reported:

Footwear revenues totaled $5.47 billion, up 8% from last year.
Apparel revenues were $2.30 billion, an increase of 3%.
Equipment revenues were $335 million, a decrease of 14%.

Wedbush has a Neutral rating with a $52 price target, implying a slight downside of 2% from Thursday’s closing price of $53.17. The firm is arguing that it will take Nike an extended period to reap the benefits from key initiatives and improve the underlying business. Wedbush detailed in its report:

Guidance also suggests that both fiscal first quarter and fiscal 2018 Street estimates should fall 20% and 5%, respectively. Shares traded up 8% after-hours, likely due to investor expectations substantially below the Street due to the restructuring announcement 2 weeks ago and strong qualitative commentary around key initiatives and products to drive growth. The fourth quarter beat, driven in part by a lower than expected tax rate and cost efficiencies that may not be sustainable given the first half 2018 outlook was notably below consensus expectations. We look for a better inflection in the fundamentals (qualitative and quantitative) and would not chase shares at current levels.

Jefferies reiterated a Buy rating with a $75 price target, implying upside of 41%. The firm believes that Nike is being smart, getting more speed, more newness and more closeness with the supply chain, the product and the consumer.

Merrill Lynch rated Nike as an Underperform rating with a mere $42 price target, implying downside of 21%. The brokerage firm said:

We expect sales and earnings growth to decelerate on market share pressures and intensifying competition. We see downside to Nike’s current P/E multiple given market share pressure in the U.S. and difficult International comparisons, which offset strong direct-to-consumer momentum and strength in China.

Oppenheimer has a Perform rating for Nike with no price target. The firm said in its report:

Nike is pulling back on less differentiated wholesale relationships (estimate as much as $500 million in lost sales in the fiscal first half of 2018), with fiscal 2018 product introductions scaling this year’s innovations (VaporMax/ZoomX); direct Amazon relationship in pilot stage allows control of product segmentation/customer interaction. Longer term, it appears Nike is making the right steps cleaning up distribution/focusing on own DTC, albeit in near term, estimates are coming down (fiscal first-quarter estimates shaping up $0.20 lower than consensus), with North America staying under pressure (fiscal 2018 guided as a hockey-stick recovery year). Staying sidelined; with inventories in North America cleaner (down 6% ending May), there could be some relief in promotional landscape in athletic.

Credit Suisse maintained its Outperform rating with a price target of $63, implying upside of 18.5%. The brokerage firm detailed:

Nike gave its strongest signal yet that it is seeking to disintermediate traditional wholesale channels as the next phase of its growth. The “triple-double” introduced the theme last quarter with the company targeting a doubling of DTC revenue, doubling of speed-to-market, and double the cadence of innovation. Guidance and company commentary this quarter provided details on the implementation, including what looks to be an aggressive curtailment of distribution into low-quality wholesale doors in developed markets. In addition, the company emphasized it expects substantial margin accretion from this DTC shift (constant currency gross margin expansion above the 30-50 basis points year over year long-term target in fiscal 2018), one of the few big question marks about this shift. With the innovation pipeline more robust than at any time in the last two years, and inventory levels finally under control, the company does look to be playing offense rather than defense again. We do expect topline growth to remain more moderate, and target a 5-7% long-term revenue growth trajectory, normalized margin expansion of 20-50 basis points year over year, and EPS growth in the low-double digits as the most likely outcome. That leaves Nike as one of the few high-ROIC large cap-consumer-discretionary growth businesses in our universe.

Shares of Nike were last seen trading up about 9% at $59.00 on Friday. The stock has a 52-week range of $49.01 to $60.33 and a consensus analyst price target of $60.59.

​NIKE ON UP SWING

The Chicago Police Department said Friday it is teaming up with federal agencies to crack down on illegal weapons and stepup the prosecution of repeat gun offenders, a move aimed at bringing down the city's violent crime rate. The effort was quickly claimed by President Trump's administration as evidence that Mr Trump has made good on his promise to bring down gun violence in the city through federal assistance. Crime and killings in Chicago have reached such epidemic proportions that I am sending in Federal help Mr Trump wrote in twitter. Several hours later, the Chicago Police Department officially made public the partnership with the federal government including  including the Bureau of Alcohol, Tobacco, Firearms and Explosives and federal prosecutors. The initiative, known as Chicago Crime Gun Strike Force, is to be led by a specialized team of Chicago officers, federal agents, state troopers and others who together will focus on the problem of illegal guns on the city's streets. The ATF plans to send 20 additional agents to Chicago for the new initiative, which will also lean heavily on federal technology and resources like a mobile ballistics testing van that can analyze shell casings at a crime scene.

A new report details the extent of Americans’ drug consumption, which are the narcotics of choice, which states’ residents spend the most to get the drugs and what some people are willing to do to get them.The report, published and funded by drug-counseling organization Addictions.com, comes at a time as more states legalize marijuana and local officials weigh the costs of legalization to their communities.A data scientist conducted the study by polling 1,000 drug users across the United States and compiling data based on their state, substance of choice and educational background.

Marijuana is the drug of choice, making up more than 70% of all drug use among those polled, followed by cocaine at 6.5%. Cocaine users spent the most money on their drug, around $83 a day, followed by heroin users ($51.60 per day). Marijuana users spend $25 a day on weed.Alaskans spend a daily average of $384 on drugs, nearly five times the average of other states.  Experts attribute this to a surging use of heroin in that state.

Other states were daily drug spending is high are Ohio ($77.50), West Virginia ($55.00), Alabama ($54.90) and Indiana ($51.00). A surge in the use of opioids is a major factor in the increase in drug spending. On the lower side, drug users in Nebraska and Idaho spend 50 cents a day, followed by Mississippi ($2.50) and North Dakota and New Mexico ($5.00).

Researchers claim that those who become addicted to cocaine could spend more than $16,000 over their lifetime on the drug. Users of ecstasy would spend $14,209 over their lifetime, the second-highest total. The report also found that college graduates are the most likely to turn to sex work to bankroll their drug habit.

Those in the study between the ages of 30 and 39 spend the most per day on their drug habit of any age cohort, $39.74 a day. Also, those with a graduate degree spend the most per day on drugs, $65.65.Drug dependence has divisive repercussions for the families of drug abusers. More than 38% of users of hallucinogenic mushrooms said they stole money from family members to support their drug use, followed by users of crack cocaine (33.0%), ecstasy (28.6%) and cocaine (28.0%)

Experts are concerned that with more states legalizing cannabis for recreational and medical use, the numbers for addiction will increase as the drug becomes more acceptable to use.Medical and recreational use of marijuana is legal in Massachusetts, Colorado, Washington, Alaska, Oregon, Nevada, California and Maine. Twenty-one states and the District of Columbia restrict marijuana for medical use only.

Opioid use has become a scourge in communities across the nation, with abuse of prescription opiates, including hydrocodone, oxycodone and fentanyl, responsible for nearly half of U.S. opioid-related deaths.

​Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk involved, should a study come back negative or should a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.

The long and short of the matter is that updates within this industry, as well as U.S. Food and Drug Administration (FDA) rulings, can make or break these companies.

24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of July and added some color, along with the trading range and price target. Note that, due to many outside and internal factors, there are no assurances that the dates will remain static. Some date changes are positive developments, and some can be disasters if a company is not deeply financed.

As a side note about the Prescription Drug User Fee Act (PDUFA): a Priority Review designation is granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease.

Also in the coming weeks, the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress in Berlin will be taking place. ISTH is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The congress hosts the world’s leading experts on thrombosis, hemostasis and vascular biology, presenting the most recent advances to improve patient care.

Spark Therapeutics Inc. (NASDAQ: ONCE) is scheduled to release interim data from its Phase 1/2 clinical trial of SPK-9001 for hemophilia B at the ISTH. The presentations from this event will take place between July 8 and 13. Overall this treatment is approaching hemophilia from the gene therapy perspective, as opposed to the preferred treatment of factor replacement in which the missing factor protein is put into the affected patient’s vein.

Shares of Spark were last seen at $59.74, with a consensus analyst price target of $70.44 and a 52-week trading range of $35.07 to $65.99.

UniQure N.V. (NASDAQ: QURE) is another company in attendance at the ISTH. Like Spark, uniQure is also a gene therapy company looking to treat hemophilia B. Matthew Kapusta, CEO of uniQure, commented:

The data to be featured in an oral presentation at ISTH now demonstrate long-term safety, efficacy and the potential for broad application of AAV5 in hemophilia B. We also look forward to the presentation of clinical data demonstrating successful and effective transduction in patients with pre-existing neutralizing antibodies to AAV5, further supporting our belief that our AAV5-based gene therapies may provide clinical benefits to nearly all patients suffering from hemophilia B and other severe diseases.

Shares of uniQure closed out the week at $6.19, within a 52-week range of $4.72 to $9.72 and a consensus price target of $12.82.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will be presenting data in a late breaking abstract session at the ISTH. Essentially, the firm will report interim results from its Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe hemophilia. This data will be presented on the morning of July 11. Management also seems very positive ahead of this presentation. Hank Fuchs, M.D., President Worldwide Research and Development at BioMarin, commented:

We are committed to further our ongoing clinical program with BMN 270, which has the potential to change the course of hemophilia A treatment, the most common form of the disease, and look forward to sharing our latest findings.

BioMarin shares were last seen at $90.82, with a consensus analyst target of $111.78 and a 52-week range of $77.04 to $102.49.

Kadmon Holdings Inc. (NYSE: KDMN) is presenting interim data from its ongoing Phase 2 clinical trial of KD025 for previously treated patients with chronic graft-versus-host disease (cGVHD). The data will be presented at the firm’s Research and Development day on July 11. For some quick background: cGVHD is a condition that might occur after a patient receives bone marrow or peripheral blood stem cells from another person. Specifically, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body.

Shares of Kadmon were most recently trading at $3.89. The stock has a 52-week range of $2.25 to $11.73 and a consensus price target of $10.54.

In June, Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) announced positive efficacy data in a Phase 3 registration study in community-acquired bacterial pneumonia, demonstrating the efficacy and general safety and tolerability of IV to once-daily oral omadacycline compared to moxifloxacin. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. This study completed enrollment in May 2017 and top-line data is expected in mid-July. Following this, the company plans to submit its new drug application (NDA) in the United States as early as the first quarter of 2018, with an EMA submission later in 2018.

Shares of Paratek were last seen at $24.10, with a consensus price target of $3.80 and a 52-week range of $9.80 to $25.95.

Ocular Therapeutix Inc. (NASDAQ: OCUL) announced back in February the resubmission of its NDA for Dextenza for the treatment of ocular pain occurring after ophthalmic surgery. This is in response to the FDA’s Complete Response Letter. The FDA determined that the NDA resubmission is a complete response and designated the resubmission as a Class 2 review, with a PDUFA target action date of July 19 for the potential approval of Dextenza.

Ocular closed out the week at $9.27 a share, in a 52-week range of $4.04 to $11.91 and with a consensus price target of $22.25.

Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) submitted its NDA of Ryanodex (dantrolene sodium) for the treatment of exertional heat stroke (EHS) for review by the FDA back in March. At that time it was also granted a priority review designation. Now its come time for the FDA to announce its decision. The PDUFA date has been set for July 23.

Scott Tarriff, CEO of Eagle, said:

There is currently no approved pharmacological treatment for EHS. If Ryanodex is approved, Eagle will be the first to market with a potentially transformational therapy. EHS can strike anyone, but athletes, our military and outdoor workers are especially vulnerable. We look forward to working with the FDA throughout the review process and to their expedited decision in July 2017.

Shares of Eagle Pharma were last seen at $78.89. The 52-week range is $38.20 to $97.15, and the consensus price target is $91.75.

HIGH TECHNOLOGY

Look for banks to tighten up their commercial real estate lending in coming months, with some shying away for CRE loans altogether. Although the scrutiny will extend to all sorts of CRE loans, it will be keenest for those for land development and construction of multifamily properties. With commerical real estate prices moderating banks are growing wary of lending for fear of extending money just as the market is passing its peak. Regulators are also concerned about the amount of bank held debt relating to commercial real estate. They worry that banks concentrated in CRE will not be able to handle a property market crash, should one rear it ugly head. Banks are under orders from the Federal Reserve to provide contingency plans for how they would cope if commercial real estate prices were to plummet 35% or more

As sellers of information technology battle powerful headwinds, global IT sales will eke out just 1% growth in 2017, up from a flat 2016. They will take a hit form a strong US dollar. Brexit uncertainty and slow global growth. Brisk sales of software and cloud computing tools are being off set by weak sales in other segments. Amazon, Google and Microsoft are scoring more deals with firms for online storage and computing cutting into sales of data centers and equipment. Some advice for companies looking for ways to keep a lid on IT spending, replace in house software with cheaper online tools. Ask IT providers to lower prices and throw in extra services for free. Hunt for deals on tablets, PCs and printers


More cities are testing out new technology in virtual worlds before they buy. Computer simulations let them learn how sensors, cameras, drones and other gear would affect infrastructure projects such as roads, bridges, buildings and parks. Vendors such as Siemens are showing cities how to cut pollution or reduce traffic by running different digital models to determine the best bang for the buck. One of the top tech challenges for cities: Preparing for driverless vehicles by improving roadways and installing better cameras, sensors and wireless networks. Many mayors are readying detailed blue prints for integrating driverless cars on roads

The government of North Korea said on Tuesday afternoon that the country had successfully launched its first intercontinental ballistic missile (ICBM). The missile reached an altitude of 1,737 miles and flew 580 miles downrange before plunging into the Sea of Japan according to North Korean news reports.At a standard trajectory, reaching an altitude of about 1,100 miles, an ICBM launched from North Korea could reach Anchorage, Alaska, according to a report at The Wall Street Journal. Whether North Korea has a nuclear warhead small enough to mount on the Hwasong-14 missile is disputed: the Koreans say they do, outside experts are split.Despite its very modest size geographically and economically, the Democratic People’s Republic of Korea (DPRK), or more commonly, North Korea, has become a major threat to global stability

Economically, North Korea is one of the poorest countries in the world. Its population of about 25 million lives in extreme poverty, with annual estimated per capita income of $1,800, according to the CIA Factbook.The country’s literacy rate is 100%, and both males and females attend school for 12 years.The life expectancy in the country is estimated at 70.4 years, comprised of an average of 66.6 years for men and 74.5 years for women. Nearly half (44%) of the population falls in the 25- to 54-year-old age category, and less than 10% of the population is over 65 years old. In the United States, just over 15% of the population is over 65 years old and less than 40% falls in the 25 to 54 age range.

North Korea’s economy is highly dependent on China. About 75% of the country’s $4.15 billion in exports are sent to China, and 76% of its $4.8 billion in imports come from China.

According to the CIA Factbook, North Korea is a source country for men, women and children who are subjected to forced labor and sex trafficking. Workers are not free to change jobs, and “tens of thousands” of North Koreans, including children, are held in prison camps and subjected to forced, heavy labor.The country’s capital city is Pyongyang and the executive branch of the DPRK’s government is headed by Kim Jong Un, the grandson of Kim Il Sung and the son of Kim Jong Il, who ruled the country since its founding in 1948. The former has been designated the Eternal President and the latter the Eternal General Secretary. The current premier is Pak Pong Ju, and there are eight vice premiers.The unicameral legislature, the Supreme People’s Assembly, is elected by citizens 17 years of age and older and serves for five-year terms. The Korean Worker’s Party selects all candidates.

The DPRK’s judicial system consists of a Supreme Court, composed of a chief justice and two “people’s assessors.” The judges are elected to five-year terms by the Supreme People’s Assembly. The system includes provincial, municipal, military, special and people’s courts.
Nearly two-thirds (63%) of the DPRK’s total labor force of 14 million works in the industry and services sectors. The remaining 37% work in agriculture. The CIA Factbook notes that unemployment ran to 25.6% in 2013, about equal to the unemployment rate in Greece.According to a U.S. Defense Department report, over 1 million soldiers serve in the Korean People’s Army. That total includes ground, air, naval, missile and special operations forces. The United States active duty roster in 2015 totaled 1.43 million. The U.S. population of about 320 million is more than 10 times that of the DPRK.

Australia’s News.com.au, in a recent report, noted that North Korea spends as much as 22% of its $40 billion GDP on its military. U.S. defense spending, though much higher at $600 billion, represents about 3.3% of U.S. 2015 GDP of more than $18 trillion.A report from Global Fire Power estimates that the DPRK’s defense budget is $7.5 billion, ranking it 23rd in the world for military spending. The country’s army includes 5,025 tanks, 4,100 armored fighting vehicles, 2,250 self-propelled guns, 4,300 towed artillery pieces and 2,400 multiple launch rocket systems.

The North Korean air force counts 944 total aircraft, including 458 fighters, 572 fixed-wing attack aircraft, 100 transport aircraft, 169 trainers, 202 helicopters and 20 attack helicopters.The North Korean navy includes a total strength of 967 vessels, including 438 coastal defense craft, 76 submarines, 25 mine-warfare ships, 11 frigates and two corvettes. The country has no aircraft carriers or destroyers.

The Defense Department report states that North Korea has been an exporter of conventional arms and ballistic missiles for several decades. Weapons sales are a critical source of foreign currency for the country, and it is unlikely to cease export activity in spite of UN Security Council sanctions.The country’s nuclear capabilities are, of course, the main threat to the United States and its allies. The Republic of Korea (South Korea) and its capital, Seoul, are threatened as well by the massive numbers of artillery and self-propelled guns that can be brought to bear on the south with less than a minute’s notice.

In his New Year’s Day speech, Kim Jong Un said:
Last year an epochal turn was brought about in consolidating the defence capability of Juche [self-reliant] Korea, and our country achieved the status of a nuclear power, a military giant, in the East which no enemy, however formidable, would dare to provoke.
We conducted the first H-bomb test, test-firing of various means of strike and nuclear warhead test successfully to cope with the imperialists’ nuclear war threats, which were growing more wicked day by day, briskly developed state-of-the-art military hardware, and entered the final stage of preparation for the test launch of intercontinental ballistic missile; we achieved other marvellous successes one after another for the consolidation of the defence capability.

Analysts at Stratfor wrote last year:
Pyongyang’s unswerving progress toward developing a nuclear capability reflects the singular obsession with which it chases its goals and why the West takes its threats seriously. … North Korea’s biggest fear is to be coerced into a position of subservience, having to prostrate itself before China (its primary benefactor) or another power country.

U.S. efforts to enlist China in stopping the DPRK’s development of nuclear weapons may stumble on the country’s determination to guarantee its own future.

​USES FOR ASPRIN

NORTH KOREA

About half of all Americans between the ages of 45 and 75 use aspirin, according to a recent survey. The drug’s popularity is attributable to its wide range of uses, from reducing a fever to treating a headache to preventing a stroke or heart attack.

Though the drug as we know it today was invented in a laboratory in Germany in 1897, humans have been using the drug’s medicinal properties for millennia. The ancient Greeks used some of aspirin’s active ingredients as early as around 400 B.C.

While many of aspirin’s uses have been known for decades if not centuries, new uses are still being discovered. 24/7 Wall St. reviewed some of the most serious and common ailments that are either treatable, or preventable, with aspirin.

Click here to see the 11 medical conditions that Aspirin can treat.

One of aspirin’s most important functions is as an analgesic — or pain reliever. While over the decades many other pain relievers have been made available over-the-counter — including those containing acetaminophen and ibuprofen — aspirin remains a popular option for pain relief.

Aspirin is also often used for its anti-inflammatory properties. Inflammation is the root cause of several conditions, including muscle aches and several types of arthritis.

Aspirin is also commonly used for its anti-platelet blood-thinning properties. Heart attack and stroke are two of the most common causes of death in the United States, and aspirin can greatly reduce the risk of both. Since strokes are caused by blood failing to reach the brain, and heart attacks are caused by blood failing to reach the heart, aspirin’s ability to thin blood and prevent it from congealing can greatly reduce the likelihood of such conditions in many of those at risk.

Heart attack and stroke are not the only deadly diseases aspirin can help and prevent and treat. Several multi-decade studies recently suggested that a low-dose aspirin regimen can reduce the likelihood of developing certain types of cancers and also increase the likelihood of survival among those undergoing treatment for certain types of cancer.

While many consider aspirin to be a miracle drug, it is not a cure-all. Though aspirin is an effective tool to fight and prevent the most common type of stroke, it can significantly worsen the effects of a different kind of stroke. In more rare cases, strokes are caused by bleeding in the brain, a condition that aspirin’s blood-thinning properties can worsen.

Aspirin can also cause gastrointestinal bleeding in some cases. People should always check with their doctor before taking aspirin.

To identify the conditions that can be treated or prevented with aspirin, 24/7 Wall St. spoke with physicians and consulted data from the Mayo Clinic and Centers for Disease Control and Prevention. Our list is comprised of some of the most common and some of the most deadly conditions and ailments treatable with aspirin.

These are the 11 medical conditions Aspirin can treat.


1. Heart disease
Annual U.S. cases: 735,000 (heart attack)

Heart disease killed more than 614,000 Americans in 2014, making it the leading cause of death in the United States. A heart attack, one of the most serious complications of heart disease, can be prevented with aspirin. Because heart attacks can be caused by blood clots that restrict blood flow to the heart, aspirin’s anti-platelet blood-thinning properties can greatly reduce the risk of a heart attack in at-risk individuals. At-risk individuals often take a low daily dose of the drug, and those suffering from a heart attack can limit damage by taking the drug as first-aid.

2. Colorectal cancer
Annual U.S. cases: 136,119

The U.S. Preventative Services Task Force announced in April 2016 that aspirin can reduce the risk of colorectal cancer in certain individuals. The multi-decade studies demonstrated that among those with a specific hereditary condition that puts them at greater risk of colorectal cancer those who took aspirin reduced their risk by 63% compared to those taking a placebo. The benefits also extend to those at average risk of colorectal cancer. Some researchers believe we are only beginning to fully understand aspirin’s potential role in fighting cancer.

3. Inflammation
Annual U.S. cases: 54.4 million (arthritis)

Aspirin’s anti-inflammatory properties make it an effective treatment for a number of common ailments. While inflammation is the body’s way of protecting itself from infection from foreign viruses and bacteria. However, it can also damage the body’s tissues and cause pain. Inflammation without a real virus or bacteria often manifests as one or more forms of arthritis, which affects millions of Americans. Aspirin can reduce pain associated with osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and muscle aches.

4. Preeclampsia
Annual U.S. cases: <200,000

Preeclampsia is a rare condition that can occur during pregnancy. Preeclampsia can cause damage to the kidneys, and if left untreated can be fatal to both the mother and the fetus. Preeclampsia is often characterized by increased blood pressure about 20 weeks or more into pregnancy, even in women with relatively normal blood pressure. A low-dose aspirin regimen is often used as a preventative measure for at-risk women


​5. Tension headaches
Annual U.S. cases: >3 million

Headaches are one of the most common medical conditions in the world, affecting roughly 1-in-20 adults on a daily basis. One common type of headache is a tension headache, characterized by a dull, aching head pain and tenderness in the neck and shoulders. Though the exact cause of tension headaches are unknown, many researchers believe they are related to heightened emotions and stress. As a pain reliever, aspirin is one of many over the counter medications that can effectively treat tension headaches.

6. Breast cancer
Annual U.S. cases: 232,924

Recent studies suggest that aspirin can increase the likelihood of survival among those suffering from a number of cancers, including breast cancer. While there is less doubt regarding aspirin’s benefits to patients with other types of cancer, such as colorectal, a low dose aspirin regimen during the course of the cancer treatment can improve chances of survival for patients with breast cancer.24/7 Wall St.
America’s Most Eco-Friendly Vehicles

7. Fever
Annual U.S. cases: >3 million (influenza)

Fever, or high body temperature, is a symptom of a number of infections, including the flu and common cold. Along with several other over-the-counter medications, including those containing acetaminophen and ibuprofen, aspirin can be an effective way to reduce a fever. Many Americans likely associate fevers with the seasonal flu, an infection that affects millions of Americans each year.

8. Stroke
Annual U.S. cases: 795,000

Strokes are one of the leading causes of death and the leading cause of adult disability in the United States. Most strokes occur when blood flow to a part of the brain is cut off. The reduced blood flow deprives the brain of oxygen and kills cells in whatever part of the brain is affected. Because of aspirin’s anti-blood clotting properties, many stroke victims are given aspirin upon arrival at the hospital to reduce the likelihood of another stroke.

In rarer instances, strokes are caused by ruptured blood vessels in the brain. In these cases, aspirin is to be avoided as the very properties that make it an effective treatment for strokes caused by clotting can make bleeding more severe.


​9. Prostate cancer
Annual U.S. cases: 176,450

Like many cancers, relatively little is known about the causes of prostate cancer. It is the second most common form of cancer among men. Though the findings are not 100% conclusive, it appears a low-dose aspirin regimen while undergoing cancer treatment can reduce the likelihood of death among patients with prostate cancer.

10. Migraine
Annual U.S. cases: >3 million

A migraine is an especially severe headache characterized by throbbing pain, often only on one side of the head. People suffering from a migraine are often hypersensitive to light and sound and can find the pain debilitating. Migraines can have many triggers that can range from stress to food additives. The root cause however, is the aggregation of blood platelets, which can often be prevented with aspirin.



​TRUMP SENDS HELP TO CHICAGO

​STOCKS AWAITING FDA APPROVAL

ALASKANS SPEND THE MOST ON DRUGS

ENERGY

Trump's top diplomatic priority is clear: Reinforce alliances with some key partners, expecially those that have gown shaky in recent years. Hence his warm relations with Israel, Saudi Arabia, and Egypt, countries he views as strategically vital to counter balance Iran's influence in the Middle East. Ditto Japan a major US ally against North Korea. Trump is not afraid to challenge allies if he thinks they are not acting in the US's interest He had harsh words for some European countries that he thinks do not do enough to support NATO, even though his remarks ruffled feathers in Europe.


America's top threat:

Islamic terrorism by ISIS and other groups. That means a major middle east focus for the president's foreign policy, promoting stability in the region and uprooting ISIS from its Syrian base.

Asia and the Pacific will be a lower priority for him than for President Obama, who devoted significant US military and diplomatic resources to the region. 

Trump sees Russia as a country to work with, not a threat to US interests, particularly in the Middle East. He will seek Moscow's help in fighting terrorism there.


Here is how Trump will handle specific foreign trouble spots and challenges.

North Korea: Unfortunately for the president, his options are limited. Military action is too risky, his advisors think, but the regime's nuclear missile work is progressing at a worry rate. So Trump will maintain US economic sanctions on Pyongyang, bolster missile defense work and hold military drills with South Korea.

Syria: Trump will stick to defeating ISIS and stay out of the civil war. One danger: US forces could clash with Iranian backed fighters as ISIS is driven out of its former territories and Iran fills the vacuum. 

NATO: He will talk tough but will keep US commitments to Europe American troops stationed in eastern Europe to counter Russia are not going any where.

Afghanstan: Trump is likely to respond to the Taliban's growing power by deploying several thousand more troops. They probably will not turn the tide against the insurgency, though. 


How sucessful Trump is abroad depends in part on his popularity at home, a rule that holds for any President. All presidents are tempted to notch achievements on the world stage when their domestic approval ratings are low. Foreign leaders are more apt to cooperate if a president has the American people solidly behind him.

​JULY NEWSLETTER

Daniel Cullinane CPA

25 Plaza 5 25th fl Jersey City NJ                                          phone 732-516-1648 fax 732-516-9778

MBA Taxation

Daniel Cullinane CPA

2500 Plaza 5 25th fl  Jersey City NJ 07311                                                          phone 732-516-1648  fax 732-516-9778

                 MBA TAXATION